Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G, Yallop D, Buggins AG, Wagner S, Kennedy BJ, Miall F, Hills R, Devereux S, Oscier DG, Dyer MJ, Fegan C, Pepper C (2010) CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res Epub
Hutchison CA, Pratt G (2010) Free light chains and renal disorders: when small is worse. Lancet 376, 1220
Weston VJ, Oldrieve CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116, 4578-4587
Hayden RE, Pratt G, Drayson MT, Bunce CM (2010). Lycorine sensitizies CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibbrate- and medroxyprogesterone acetate induced apoptosis but dasatinib does not overcome reported CD40-mediated drug resistance. Haematologica 95, 1889-1896
Smith HJ, Hanvesakaul R, Morgan MD, Bentall A, Briggs D, Clark F, Pratt G, Moss P, Larche M, Ball S (2010). Chronic Graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptides. Transplantation 90, 555-563
Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, Fegan C, Pepper C, Baird DM (2010). Telomere dysfunction and fusion during the progression of a human malignancy. Blood 116, 1899-1907
Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C (2010). The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Mol Cancer Ther. 9, 1574-1582.
McLarnon A, Piper K, Goodyear O, Arrazi J, Mahendra P, Cook M, Clark F, Pratt G, Craddock C, Moss P (2010). CD8+ T cell immunity against cancer testis antigens develops following allogeneic stem cell transplantation and reveals a novel mechanism for graft versus leukaemia. Haematologica 95, 1572-1578